Immunomodulators Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)

$ PRICE - $ 3,000.00$ 8,900.00

Immunomodulators Market: By Product (Immunosuppressants(Antibodies, Calcineurin inhibitors, Glucocorticoids, Antimetabolites) Immunostimulants(Vaccines, Antibodies) Application(Oncology, Respiratory, HIV) and Geography

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

Immunomodulators Market size is valued at USD 185.1 billion in 2021 and is expected to reach a value of USD 287.6 million by 2028, growing at a CAGR of 6.5% during the forecast period 2022 to 2028. The global market provides a detailed overview of the immunomodulators market and that can be segmented by product and application. By product, the immunomodulators market has been segmented into immunosuppressants and immunostimulants. The immunosuppressants segment is likely to be the largest and fastest-growing segment in terms of product. The immunosuppressants segment is further segmented into antibodies, calcineurin inhibitors, glucocorticoids, and antimetabolites. Immunostimulants is segregated into vaccines and antibodies. Based on application, the immunomodulators market is segmented into oncology, respiratory, and HIV. Among these, the oncology segment is expected to have the fastest-growing market during the forecast period 2022-2028.

Key Developments:

In Feb 2021, PFIZER and BioNTech have begun research to eliminate COVID-19 boosters and new vaccine varieties as part of a bigger development plan.


Immunomodulators Market

MARKET SUMMARY
-
6.5%
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 6.5%
  • Fastest Growing Market–  North America

Immunomodulators Market

  • The Immunomodulators Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The Immunomodulators Market is segmented based on by product , application and geography
Key Players
  • Hoffmann-La Roche Ltd
  • Novartis AG
  • Biogen
  • Teva Pharmaceutical Industries Ltd.
  • Amgen, Inc
  • Bristol-Myers and Squibb Company
  • Merck Sharp and Dohme Corp.
  • Eli Lilly and Company

Immunomodulators Market Drivers

The rising prevalence of chronic diseases like as asthma, cancer, allergy ailments, and multiple sclerosis is a major contributor to the global Immunomodulators Market’s expansion. In addition, the increased use of early immunomodulator therapy for the treatment of Crohn’s disease is boosting the market’s growth. The availability of significant unmet clinical requirements in the treatment of immunological illnesses, such as rheumatoid arthritis, is driving this vertical’s expansion.


North-America Got Significant Share

Immunomodulators Market

By region, the North American market is expected to witness the highest market share during the forecast period. Their dominance is explained by the presence of a large ill population in this area. As a result, growing end-user demand for immunomodulator-based treatment and the high therapy costs associated with treating multiple sclerosis with these immunotherapeutic drugs are likely to drive revenue growth in this category. Due to the availability of supportive government programs and improved awareness among end-users, immunomodulatory drugs are in high demand.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The immunomodulators market report provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The immunomodulators market report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The immunomodulators market report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The immunomodulators market report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The immunomodulators market report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Immunomodulators Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The Immunomodulators Market is projected to expand at a CAGR of 6.5% during the forecast period.

The major players in the global Immunomodulators Market are Hoffmann-La Roche Ltd (Basel, Switzerland), Novartis AG (Basel, Switzerland), Biogen (Massachusetts, U.S.), Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel), Amgen, Inc (California, U.S.), Bristol-Myers and Squibb Company (New York, U.S), Merck Sharp and Dohme Corp. (New jersey, U.S) and Eli Lilly and Company (Indiana, U.S).

North America is the fastest-growing region for Immunomodulators Market


Report

Table Of Content

1. Executive Summary
2. Global Immunomodulators Market Introduction
2.1. Global Immunomodulators Market – Taxonomy
2.2. Global Immunomodulators Market –Definitions
2.2.1. By Product
2.2.2. By Application
2.2.3. By Region
3. Global Immunomodulators Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Immunomodulators Market Dynamic Factors – Impact Analysis
3.6. Global Immunomodulators Market – Competition Landscape
4. Global Immunomodulators Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Immunomodulators Market, By Product, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
5.1. Immunosuppressants
5.1.1. Antibodies
5.1.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.1.3. Market Opportunity Analysis
5.1.2. Calcineurin inhibitors
5.1.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.2.3. Market Opportunity Analysis
5.1.3. Glucocorticoids
5.1.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3.3. Market Opportunity Analysis
5.1.4. Antimetabolites
5.1.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.4.3. Market Opportunity Analysis
5.1.5. Others
5.1.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.5.3. Market Opportunity Analysis
5.2. Immunostimulants
5.2.1. Vaccines
5.2.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.1.3. Market Opportunity Analysis
5.2.2. Antibodies
5.2.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.2.3. Market Opportunity Analysis
5.2.3. Others
5.2.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3.3. Market Opportunity Analysis
6. Global Immunomodulators Market, By Application, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
6.1. Oncology
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Respiratory
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. HIV
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. Global Immunomodulators Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
7.1. North America
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Immunomodulators Market – Opportunity Analysis Index, By Product, Application, and Region, 2022 – 2028
8. North America Immunomodulators Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
8.1. Product Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Immunosuppressants
8.1.1.1. Antibodies
8.1.1.2. Calcineurin inhibitors
8.1.1.3. Glucocorticoids
8.1.1.4. Antimetabolites
8.1.1.5. Others
8.1.2. Immunostimulants
8.1.2.1. Vaccines
8.1.2.2. Antibodies
8.1.2.3. Others
8.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Oncology
8.2.2. Respiratory
8.2.3. HIV
8.2.4. Others
8.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. USA
8.3.2. Canada
8.4. North America Immunomodulators Market – Opportunity Analysis Index, By Product, Application, and Country, 2022 – 2028
8.5. North America Immunomodulators Market Dynamics – Trends
9. Europe Immunomodulators Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
9.1. Product Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Immunosuppressants
9.1.1.1. Antibodies
9.1.1.2. Calcineurin inhibitors
9.1.1.3. Glucocorticoids
9.1.1.4. Antimetabolites
9.1.1.5. Others
9.1.2. Immunostimulants
9.1.2.1. Vaccines
9.1.2.2. Antibodies
9.1.2.3. Others
9.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Oncology
9.2.2. Respiratory
9.2.3. HIV
9.2.4. Others
9.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Russia
9.3.7. Rest of Europe
9.4. Europe Immunomodulators Market – Opportunity Analysis Index, By Product, Application, and Country, 2022 – 2028
9.5. Europe Immunomodulators Market Dynamics – Trends
10. Asia-Pacific Immunomodulators Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
10.1. Product Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Immunosuppressants
10.1.1.1. Antibodies
10.1.1.2. Calcineurin inhibitors
10.1.1.3. Glucocorticoids
10.1.1.4. Antimetabolites
10.1.1.5. Others
10.1.2. Immunostimulants
10.1.2.1. Vaccines
10.1.2.2. Antibodies
10.1.2.3. Others
10.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Oncology
10.2.2. Respiratory
10.2.3. HIV
10.2.4. Others
10.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Immunomodulators Market – Opportunity Analysis Index, By Product, Application, and Country, 2022 – 2028
10.5. Asia-Pacific Immunomodulators Market Dynamics – Trends
11. Latin America Immunomodulators Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
11.1. Product Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Immunosuppressants
11.1.1.1. Antibodies
11.1.1.2. Calcineurin inhibitors
11.1.1.3. Glucocorticoids
11.1.1.4. Antimetabolites
11.1.1.5. Others
11.1.2. Immunostimulants
11.1.2.1. Vaccines
11.1.2.2. Antibodies
11.1.2.3. Others
11.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Oncology
11.2.2. Respiratory
11.2.3. HIV
11.2.4. Others
11.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Rest of Latin America
11.4. Latin America Immunomodulators Market – Opportunity Analysis Index, By Product, Application, and Country, 2022 – 2028
11.5. Latin America Immunomodulators Market Dynamics – Trends
12. Middle East and Africa Immunomodulators Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
12.1. Product Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Immunosuppressants
12.1.1.1. Antibodies
12.1.1.2. Calcineurin inhibitors
12.1.1.3. Glucocorticoids
12.1.1.4. Antimetabolites
12.1.1.5. Others
12.1.2. Immunostimulants
12.1.2.1. Vaccines
12.1.2.2. Antibodies
12.1.2.3. Others
12.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Oncology
12.2.2. Respiratory
12.2.3. HIV
12.2.4. Others
12.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Immunomodulators Market – Opportunity Analysis Index, By Product, Application, and Country, 2022 – 2028
12.5. MEA Immunomodulators Market Dynamics – Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Hoffmann-La Roche Ltd (Basel, Switzerland)
13.2.2. Novartis AG (Basel, Switzerland)
13.2.3. Biogen (Massachusetts, U.S.)
13.2.4. Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel)
13.2.5. Amgen, Inc (California, U.S.)
13.2.6. Bristol-Myers and Squibb Company (New York, U.S)
13.2.7. Merck Sharp and Dohme Corp. (New jersey, U.S)
13.2.8. Eli Lilly and Company (Indiana, U.S)
14. Research Methodology
15. Key Assumptions and Acronyms

Report

Company Profile

  • Hoffmann-La Roche Ltd (Basel, Switzerland)
  • Novartis AG (Basel, Switzerland)
  • Biogen (Massachusetts, U.S.)
  • Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel)
  • Amgen, Inc (California, U.S.)
  • Bristol-Myers and Squibb Company (New York, U.S)
  • Merck Sharp and Dohme Corp. (New jersey, U.S)
  • Eli Lilly and Company (Indiana, U.S)

Description

Immunomodulators Market size is valued at USD 185.1 billion in 2021 and is expected to reach a value of USD 287.6 million by 2028, growing at a CAGR of 6.5% during the forecast period 2022 to 2028. The global market provides a detailed overview of the immunomodulators market and that can be segmented by product and application. By product, the immunomodulators market has been segmented into immunosuppressants and immunostimulants. The immunosuppressants segment is likely to be the largest and fastest-growing segment in terms of product. The immunosuppressants segment is further segmented into antibodies, calcineurin inhibitors, glucocorticoids, and antimetabolites. Immunostimulants is segregated into vaccines and antibodies. Based on application, the immunomodulators market is segmented into oncology, respiratory, and HIV. Among these, the oncology segment is expected to have the fastest-growing market during the forecast period 2022-2028.

Key Developments:

In Feb 2021, PFIZER and BioNTech have begun research to eliminate COVID-19 boosters and new vaccine varieties as part of a bigger development plan.

Reviews

There are no reviews yet.

Be the first to review “Immunomodulators Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)”

Your email address will not be published. Required fields are marked *

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX